EMJ Cardiology最新文献_第3页

The Clock Is Ticking: The Imminent Need to Re-evaluate the Standard of Care in the 90-Day High-Risk Post-Acute Myocardial Infarction Period 时间紧迫:迫切需要重新评估急性心肌梗死后90天高危期的护理标准

EMJ Cardiology Pub Date : 2022-08-26 DOI: 10.33590/emjcardiol/22c9177

OPEN Health

{"title":"The Clock Is Ticking: The Imminent Need to Re-evaluate the Standard of Care in the 90-Day High-Risk Post-Acute Myocardial Infarction Period","authors":"OPEN Health","doi":"10.33590/emjcardiol/22c9177","DOIUrl":"https://doi.org/10.33590/emjcardiol/22c9177","url":null,"abstract":"This CSL Behring-supported symposium took place during the European Society of Cardiology (ESC) 2021 Congress. Experts P. Gabriel Steg Cardiology Department, Hôpital Bichat-Claude-Bernard, Paris, France, and the Université de Paris, France; and Kausik Ray, Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, UK; Imperial Clinical Trials Unit, Imperial College London, UK; and Commercial Trials, Imperial College London, UK, discussed the clinical significance of the early post-acute myocardial infarction\u0000(AMI) period and the risk of recurrent events despite optimal recommended standard of care.\u0000\u0000Steg highlighted data from a retrospective registry study as well as several randomised controlled trials, suggesting that recurrent cardiovascular (CV) events appeared to accrue quickly in the early post-AMI period. He proposed that this may be an important timeframe for additional therapeutic interventions and warrants further investigation. \u0000\u0000Ray highlighted guideline recommendations for secondary prevention, currently focused on lipid-lowering and antiplatelet therapies. Ray presented data from several randomised controlled trials of lipid-lowering therapies, demonstrating that despite therapeutic advances and guideline-recommended treatments, there is a residual risk of recurrent CV events post-AMI. Ray suggested that additional therapeutic targets should be explored to further reduce the incidence of recurrent CV events post-AMI.","PeriodicalId":284912,"journal":{"name":"EMJ Cardiology","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115369832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EAN Congress Interview – Einar August Høgestøl

EMJ Cardiology Pub Date : 2022-08-09 DOI: 10.33590/emjneurol/10192391

E. Høgestøl

引用次数: 0

Screening for Heart Disease in the Age of Digital Health Technologies: Who, When, and How? 数字健康技术时代的心脏病筛查:何人、何时、如何?

EMJ Cardiology Pub Date : 2022-06-29 DOI: 10.33590/emjcardiol/22-00093

Edward Richardson, A. Hall, Chris Hare, P. L. Le Page, Andrew R J Mitchell

引用次数: 0

Silent Myocardial Infarction in Hypereosinophilic Syndrome Overlapped with JAK2-Mediated Essential Thrombocytosis: A Case Report 高嗜酸性粒细胞综合征与jak2介导的原发性血小板增多重叠的无症状心肌梗死:1例报告

EMJ Cardiology Pub Date : 2022-04-19 DOI: 10.33590/emjcardiol/21-00247

Shams Reaz, Christianne Jafari

引用次数: 0

Undiagnosed Hidradenitis Suppurativa Associated with Acute Myocardial Infarction: A Case Report 未确诊化脓性汗腺炎伴急性心肌梗死1例

EMJ Cardiology Pub Date : 2022-03-21 DOI: 10.33590/emjcardiol/21-00229

Uzma Gul, Khin Kay Kay Kyaw, S. Munir

{"title":"Undiagnosed Hidradenitis Suppurativa Associated with Acute Myocardial Infarction: A Case Report","authors":"Uzma Gul, Khin Kay Kay Kyaw, S. Munir","doi":"10.33590/emjcardiol/21-00229","DOIUrl":"https://doi.org/10.33590/emjcardiol/21-00229","url":null,"abstract":"Hidradenitis suppurativa (HS) is a chronic inflammatory disease believed to be a risk factor for cardiovascular events. Traditional cardiovascular risk factors, such as metabolic syndrome, often coexist with HS. Chronic inflammatory conditions may underlie cardiovascular events in young patients or those with few traditional risk factors. A 34-year-old female was admitted to the authors’ tertiary care hospital with acute anterior ST-segment elevation myocardial infarction, and underwent a successful primary percutaneous coronary intervention to their left anterior descending artery. They were a smoker, had a high BMI, and had a positive family history of premature coronary artery disease. During their admission, the patient disclosed that they had discharging lesions under their left breast. The patient had a long-standing history of multiple discharging lesions alternating with disfiguring scars that had started in their late childhood; however, despite this leading to self-dissatisfaction, they did not seek medical advice.\u0000\u0000Examination revealed plaques and scarring in both axillae and a chronic abscess under the left breast, the swabs from which were sterile, as is consistent with HS. The laboratory results showed a raised troponin and white cell count with mildly elevated levels of C-reactive protein. The patient was managed with standard acute coronary syndrome treatment and a course of oral doxycycline, and awaits further treatment by dermatology and plastic surgery. The morbidity of HS is grossly underestimated. This case study highlights that HS has significant cardiovascular implications, in addition to psychological impacts, and that underlying systemic inflammation may promote rapid atherosclerosis. Further research into pathogenesis and strategies to prevent adverse cardiovascular events are needed.","PeriodicalId":284912,"journal":{"name":"EMJ Cardiology","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129329955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Idarucizumab in Emergent Pericardiocentesis: A Case Report of Dabigatran-Induced Haemopericardium and Cardiac Tamponade 依达鲁珠单抗用于急诊心包穿刺:达比加群诱导心包积血和心包填塞1例报告

EMJ Cardiology Pub Date : 2022-02-21 DOI: 10.33590/emjcardiol/21-00165

Elisabetta Palmerini, F. De Tommasi, Tamara Taddei, S. Amidei, G. Falsini

引用次数: 0

Hydroxychloroquine- and Azithromycin-Induced Transient Left-Bundle Branch Block in a Patient with COVID-19 羟氯喹和阿奇霉素致COVID-19患者短暂性左束支传导阻滞

EMJ Cardiology Pub Date : 2021-10-11 DOI: 10.33590/emjcardiol/20-00246

Layal Mansour, Soha Fakhreddine, M. Saliba, S. Kabbani

引用次数: 0

2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2021 ESC急性和慢性心力衰竭诊断和治疗指南

EMJ Cardiology Pub Date : 2021-10-11 DOI: 10.33590/emjcardiol/21f1011

Natasha Meunier-McVey

引用次数: 457

Biomarker-Based Guideline-Directed Medical Therapy of Heart Failure: The Gap Between Guidelines and Clinical Practice 基于生物标志物的心力衰竭指导医学治疗:指南与临床实践之间的差距

EMJ Cardiology Pub Date : 2021-10-11 DOI: 10.33590/emjcardiol/20-00012

Alexander E. Berezin, Alexander A. Berezin

{"title":"Biomarker-Based Guideline-Directed Medical \u0000Therapy of Heart Failure: The Gap Between \u0000Guidelines and Clinical Practice","authors":"Alexander E. Berezin, Alexander A. Berezin","doi":"10.33590/emjcardiol/20-00012","DOIUrl":"https://doi.org/10.33590/emjcardiol/20-00012","url":null,"abstract":"Current clinical recommendations provided by the 2016 European Society of Cardiology (ESC) and 2017 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) are substantially distinguished in the use of circulating biomarkers in the management of heart failure (HF). To date, natriuretic peptides continue being the universal biomarkers used in diagnosis, risk stratification, and prediction of cardiovascular death, all-cause mortality, and HF-related outcomes for patients with both phenotypes of HF. However, biomarkers of fibrosis and inflammation, including soluble suppressor of tumourgenicity 2 and galectin-3, were able to increase predictive ability of natriuretic peptides in HF patients regardless of cardiovascular risk-factor presentation and HF phenotypes. Therefore, there are many various biomarkers describing several pathophysiological processes such as fibrosis, inflammation, oxidative stress, neurohumoral activation, extracellular matrix turnover, and vascular reparation, that play a pivotal role in the natural evolution of HF. This review discusses whether multiple biomarker models are more effective than a single biomarker in improving risk stratification strategies in patients with HF. It emphasises how in routine clinical practice, the multiple biomarker approach to elicit response to therapy of HF and predict clinical outcomes is rare, probably because of the relatively high cost, low affordability, lack of clear recommendations for clinical implementation, and significant disagreements in the interpretation of the data obtained.","PeriodicalId":284912,"journal":{"name":"EMJ Cardiology","volume":"287 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131423870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

A Case Series of Eight Coronary Artery Perforations and a Review of the Up-to-Date Literature 8例冠状动脉穿孔病例系列及最新文献综述

EMJ Cardiology Pub Date : 2021-10-11 DOI: 10.33590/emjcardiol/21-00084

S. James, George Hunter

引用次数: 0